Grandfield & Dodd LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 79,604 shares of the biopharmaceutical company’s stock after selling 3,090 shares during the period. Grandfield & Dodd LLC’s holdings in Pfizer were worth $4,079,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Front Street Capital Management Inc. grew its stake in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 215 shares in the last quarter. Lindenwold Advisors grew its stake in Pfizer by 1.0% during the 3rd quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock valued at $926,000 after acquiring an additional 216 shares in the last quarter. SRS Capital Advisors Inc. grew its stake in shares of Pfizer by 1.6% in the 2nd quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 218 shares during the period. Signet Financial Management LLC grew its stake in shares of Pfizer by 0.6% in the 3rd quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock valued at $1,503,000 after buying an additional 220 shares during the period. Finally, Mitchell Mcleod Pugh & Williams Inc. grew its stake in shares of Pfizer by 0.7% in the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 33,978 shares of the biopharmaceutical company’s stock valued at $1,487,000 after buying an additional 222 shares during the period. 67.62% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Stock Performance
PFE opened at $40.25 on Thursday. The company has a market capitalization of $227.19 billion, a price-to-earnings ratio of 7.34, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00. Pfizer Inc. has a 1-year low of $39.23 and a 1-year high of $56.32. The business has a 50 day moving average price of $42.16 and a two-hundred day moving average price of $45.70.
Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. The company had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.08 earnings per share. Research analysts predict that Pfizer Inc. will post 3.3 EPS for the current fiscal year.
Insider Buying and Selling at Pfizer
In other news, major shareholder Pfizer Inc bought 1,811,594 shares of the business’s stock in a transaction on Friday, March 17th. The shares were bought at an average cost of $2.76 per share, with a total value of $4,999,999.44. Following the purchase, the insider now directly owns 5,952,263 shares in the company, valued at $16,428,245.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.05% of the company’s stock.
Wall Street Analysts Forecast Growth
PFE has been the subject of several analyst reports. Morgan Stanley dropped their price target on shares of Pfizer from $53.00 to $45.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 1st. Jefferies Financial Group started coverage on shares of Pfizer in a report on Monday, March 6th. They issued a “hold” rating and a $43.00 price objective on the stock. Wells Fargo & Company reduced their target price on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a report on Friday, March 17th. Atlantic Securities reduced their target price on shares of Pfizer from $50.00 to $46.00 and set a “neutral” rating on the stock in a report on Wednesday, February 1st. Finally, UBS Group set a $45.00 price objective on shares of Pfizer in a research report on Tuesday, March 14th. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $50.38.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Featured Stories
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.